Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease.


Journal

The American journal of pathology
ISSN: 1525-2191
Titre abrégé: Am J Pathol
Pays: United States
ID NLM: 0370502

Informations de publication

Date de publication:
06 2019
Historique:
received: 17 04 2018
revised: 15 02 2019
accepted: 21 02 2019
pubmed: 31 3 2019
medline: 31 1 2020
entrez: 31 3 2019
Statut: ppublish

Résumé

Hepatic veno-occlusive disease (HVOD), alias sinusoidal obstruction syndrome, may develop as a complication of chemotherapy in the setting of hematopoietic stem cell transplantation. HVOD is less frequently described after exposure to chemotherapy in the nontransplant setting and can also be a complication after ingestion of toxins, such as pyrrolizidine alkaloids. Veno-occlusive disease may also affect the lungs, and it is therefore termed pulmonary veno-occlusive disease (PVOD). Similarly, PVOD can develop after exposure to chemotherapeutic agents in the treatment of solid and hematological malignancies. In addition, PVOD has also been linked to autoimmune disorders and occupational solvent exposure. Finally, the heritable form of PVOD is due to biallelic mutations of the EIF2AK4 gene. Both HVOD and PVOD share common histopathological features and pathophysiologic mechanisms. Both clinical disorders are rare complications that can appear after exposure to the common inciting trigger of chemotherapeutic agents. The present review aims to summarize the current knowledge of HVOD and PVOD and to describe both similarities as well as differences regarding both conditions.

Identifiants

pubmed: 30926335
pii: S0002-9440(18)30320-1
doi: 10.1016/j.ajpath.2019.02.007
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1159-1175

Informations de copyright

Copyright © 2019 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Sven Günther (S)

Department of Respiratory Physiology, Cochin Hospital, University Paris Descartes, Sorbonne Paris Cité, Paris, France.

Frédéric Perros (F)

INSERM UMR_S 999, Pulmonary Arterial Hypertension: Physiopathology and Therapeutic Innovation, Marie Lannelongue Hospital, Le Plessis-Robinson, France.

Pierre-Emmanuel Rautou (PE)

INSERM UMR 970, Paris Cardiovascular Research Center, University Paris Descartes, Paris, France; University Hospital Department of Unity, Department of Hepatology, Beaujon Hospital, Hôpitaux de Paris, Clichy, France.

Barbara Girerd (B)

INSERM UMR_S 999, Pulmonary Arterial Hypertension: Physiopathology and Therapeutic Innovation, Marie Lannelongue Hospital, Le Plessis-Robinson, France; Department of Respiratory Medicine, University Paris-Sud, Medical School, University Paris-Saclay, Hôpitaux de Paris, National Reference Center for Severe Pulmonary Hypertension, Bicêtre Hospital, Le Kremlin Bicêtre, France.

Maria-Rosa Ghigna (MR)

Department of Pathology, Marie Lannelongue Hospital, Le Plessis-Robinson, France.

Dominique Cazals-Hatem (D)

Department of Pathology, Beaujon Hospital, Hôpitaux de Paris, Clichy, France.

Edmund M Lau (EM)

Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Peter Dorfmüller (P)

Department of Pathology, University Hospital Giessen/Marburg and German Centre for Lung Research, Giessen, Germany.

Olivier Sitbon (O)

INSERM UMR_S 999, Pulmonary Arterial Hypertension: Physiopathology and Therapeutic Innovation, Marie Lannelongue Hospital, Le Plessis-Robinson, France; Department of Respiratory Medicine, University Paris-Sud, Medical School, University Paris-Saclay, Hôpitaux de Paris, National Reference Center for Severe Pulmonary Hypertension, Bicêtre Hospital, Le Kremlin Bicêtre, France.

Dominique C Valla (DC)

INSERM UMR 970, Paris Cardiovascular Research Center, University Paris Descartes, Paris, France; University Hospital Department of Unity, Department of Hepatology, Beaujon Hospital, Hôpitaux de Paris, Clichy, France.

Marc Humbert (M)

INSERM UMR_S 999, Pulmonary Arterial Hypertension: Physiopathology and Therapeutic Innovation, Marie Lannelongue Hospital, Le Plessis-Robinson, France; Department of Respiratory Medicine, University Paris-Sud, Medical School, University Paris-Saclay, Hôpitaux de Paris, National Reference Center for Severe Pulmonary Hypertension, Bicêtre Hospital, Le Kremlin Bicêtre, France.

David Montani (D)

INSERM UMR_S 999, Pulmonary Arterial Hypertension: Physiopathology and Therapeutic Innovation, Marie Lannelongue Hospital, Le Plessis-Robinson, France; Department of Respiratory Medicine, University Paris-Sud, Medical School, University Paris-Saclay, Hôpitaux de Paris, National Reference Center for Severe Pulmonary Hypertension, Bicêtre Hospital, Le Kremlin Bicêtre, France. Electronic address: david.montani@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH